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Infection with high-risk genital human papillomavirus (HPV) types is a major risk factor for the development of cervical intraepithelial
neoplasia (CIN) and invasive cervical carcinoma. The design of effective immunotherapies requires a greater understanding of how
HPV-specific T-cell responses are involved in disease clearance and/or progression. Here, we have investigated T-cell responses to
five HPV16 proteins (E6, E7, E4, L1 and L2) in women with CIN or cervical carcinoma directly ex vivo. T-cell responses were
observed in the majority (78%) of samples. The frequency of CD4þ responders was far lower among those with progressive
disease, indicating that the CD4þ T-cell response might be important in HPV clearance. CD8þ reactivity to E6 peptides was
dominant across all disease grades, inferring that E6-specific CD8þ T cells are not vitally involved in disease clearance. T-cell
responses were demonstrated in the majority (80%) of cervical cancer patients, but are obviously ineffective. Our study reveals
significant differences in HPV16 immunity during progressive CIN. We conclude that the HPV-specific CD4þ T-cell response should
be an important consideration in immunotherapy design, which should aim to target preinvasive disease.
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Cervical carcinoma is the second most common female cancer
worldwide, with 400000 new cases diagnosed each year (Boyle,
1997; Landis et al, 1998). Infection by human papillomavirus
(HPV) is a major risk factor for the development of invasive
cervical carcinoma and its precursor cervical intraepithelial
neoplasia (CIN). Nearly all (99.7%) cervical cancers are positive
for HPV DNA, with HPV type 16 (HPV16) being the most
prevalent and present in up to 70% of cervical cancers regardless
of geographical origin (Bosch et al, 1995; Walboomers et al, 1999).
It is clear that there are effective host defence mechanisms
against HPVs. Genital infection with HPV is generally transient,
with the majority of individuals showing clearance of the virus
within 1 year of detection (Evander et al, 1995; Ho et al, 1998;
Woodman et al, 2001; Sellors et al, 2003). In fact, only a minority
of women develop persistent infections with focally high levels of
HPV DNA, and only some of these progress to high-grade disease
and invasive carcinoma (Herrero et al, 2000). Cell-mediated
immunity is believed to be critical in the resolution and control
of HPV. HIV-infected patients show multiple recurrences of
cervical HPV infections (Fruchter et al, 1998) and an increased
incidence of genital warts (Fennema et al, 1995) that appear to
reflect an increased risk of progression from subclinical to clinical
infection (Chirgwin et al, 1995).
There are several studies providing information about CD4þ T-
cell responses to HPV16. Using either fusion proteins, panels of
overlapping peptides, or virus-like particles (VLPs), CD4 re-
sponses to HPV16 E6 (Cubie et al, 1989; Strang et al, 1990;
Nakagawa et al, 1996; Tsukui et al, 1996; Kadish et al, 1997, 2002;
Welters et al, 2003; de Jong et al, 2004), E7 (Cubie et al, 1989;
Strang et al, 1990; Altmann et al, 1992; Kadish et al, 1994, 1997,
2002; de Gruijl et al, 1996a,b, 1998; Luxton et al, 1996; Nakagawa
et al, 1996; Tsukui et al, 1996; Hopfl et al, 2000; van der Burg et al,
2001; Welters et al, 2003), E2 (Bontkes et al, 1999; de Jong et al,
2002, 2004; Welters et al, 2003), E5 (Gill et al, 1998), E4 (Cubie
et al, 1989; Nakagawa et al, 1996) and L1 (Strang et al, 1990;
Nakagawa et al, 1996; Shepherd et al, 1996; Luxton et al, 1997; de
Gruijl et al, 1999) have been demonstrated in both patient and
healthy control populations. No clear pattern has yet emerged as to
which of these responses, if any, might be associated with
regression or progression of disease as only a limited number of
prospective studies have been carried out.
The role of naturally occurring cytotoxic T cells (CTLs) in
mediating regression of HPV-related disease has not been proven.
Using a variety of restimulation protocols, HPV16 E2-, E6- and E7-
specific CTLs can be detected in patients with previous (Nakagawa
et al, 1997) or ongoing HPV infections (Alexander et al, 1996;
Borysiewicz et al, 1996; Evans et al, 1996, 1997; Ressing et al, 1996;
Jochmus et al, 1997; Konya et al, 1997; Nimako et al, 1997). Most
of this work has involved the use of selected peptides bound to the
surface of various target cells to restimulate CD8 responses in
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svitro. As such, these experiments are restricted to only a few HLA
alleles using peptides that may not be representative of HPV
epitopes expressed during natural infection. Studies using whole
HPV proteins to restimulate CTL responses, either in a soluble
form (Nakagawa et al, 1997) or expressed by recombinant viral
vectors (Nimako et al, 1997), where the whole protein is naturally
processed, have been more successful. Autologous dendritic cells
(DCs) presenting HPV16 peptides or whole proteins have also been
used to restimulate E6- and E7-specific CTL responses from both
normal donors and women with cervical carcinoma in vitro
(Murakami et al, 1999; Schoell et al, 1999; Thornberg et al, 2000;
Davidson et al, 2001; Liu et al, 2001; Chiriva-Internati et al, 2002;
Valdespino et al, 2005), although it is not clear whether these
represent primary or memory T-cell responses. Overall, the results
suggest that naturally occurring HPV E6- and E7-specific CTLs do
exist in patients with HPV-associated disease, although their
detection may depend on the methods used to reactivate them in
vitro. More recently, using tetramer technology, it has been shown
directly that HPV16 E7-specific CTLs do exist in the peripheral
blood of women with high-grade CIN and cervical carcinoma, but
they are extremely rare (Youde et al, 2000). Very little is known
about the HPV16-specific CTL response to proteins other than E6
and E7.
The link between HPV16 and cervical carcinoma opens up the
possibility of immune T-cell intervention, either against the
preinvasive lesions from which tumours arise, or against the virus
antigen-positive tumour cells themselves. To effect such strategies
will require a better understanding of the spectrum of T-cell
responses induced by HPV16 antigens during the course of natural
infection, and of their role in disease clearance and/or progression.
Much of the work to date has understandably focused on responses
to the E6 and E7 transforming proteins, since these are the only
viral antigens constitutively expressed in HPV-positive tumour
cells. By contrast, there has been no concerted effort to look at the
totality of responses to a single agent, including responses to viral
antigens that are expressed later in the replication cycle that may
be useful targets for the treatment of preinvasive lesions. In this
study, we have used CD4- and CD8-depleted populations of
responder cells in an ELISPOT assay of IFN-g release to screen
directly ex vivo for both CD4þ and CD8þ T-cell responses to five
HPV16 proteins (E6, E7, E4, L1 and L2) from a cohort of 41 women
with varying grades of cervical disease. The frequency, magnitude
and antigen specificity of the responses obtained are discussed in
relation to disease severity.
MATERIALS AND METHODS
Patients and controls
A total of 41 women attending colposcopy clinics or undergoing
surgery for cervical disease (Department of Gynaecological
Oncology, Birmingham Women’s Hospital, Birmingham, UK)
were investigated. Ethical approval for this study was obtained
from the South Birmingham Research Ethics Committee (Study
Number 5147) and informed consent was obtained from all
subjects. Abnormal cervical cytology was diagnosed and confirmed
by histopathology. Patients were assigned to one of four groups
according to the histology reports obtained from cervical tissue
taken at the time they were bled: those reported to have no
evidence of CIN, those with low-grade disease (CIN I), high-grade
disease (CIN II/III) and those with cervical carcinoma. The clinical
details are shown in Table 1.
The HPV genotype of patient biopsies obtained during the
course of this study could not be established. However, the
transient nature of genital HPV infections questions the validity of
HPV typing at a single time point, since this may not necessarily
reflect a past history of HPV infection in a significant proportion
of women, especially those with low-grade disease (Woodman
et al, 2001). High-grade disease would be expected to be associated
with a more persistent HPV infection.
Nine age-matched female virgins were recruited as negative
controls. Virginity was established by gynaecologists who obtained
full clinical and sexual histories. Normal healthy donors were
considered not suitable as a negative control group, since the
evidence suggests that a significant number will have encountered
this virus (Woodman et al, 2001). Indeed, many recent studies
have demonstrated HPV16-specific T-cell responses in normal
donors (de Jong et al, 2002, 2004; Welters et al, 2003) and HPV16
Table 1 Clinical details
Disease grade
Virgins (n¼9) No CIN (n¼12) Low grade (n¼8) High grade (n¼16) Cancer (n¼5)
Patient
Age
(years) Patient
Age
(years) Patient
Age
(years)
Histology
grade Patient
Age
(years)
Histology
grade Patient
Age
(years)
1 27 2 30 7 39 CIN I 8 26 CIN III 1 44
2 63 4 37 10 75 CIN I 9 37 CIN II 3 45
3 29 6 44 11 25 CIN I 12 26 CIN II 5 40
4 76 13 52 14 37 CIN I 19 29 CIN III 22 37
5 67 15 37 17 23 CIN I 23 27 CIN III 25 NA
6 42 16 42 21 35 CIN I 26 36 CIN III
7 35 18 29 24 56 CIN I 29 29 CIN III
8 78 20 49 28 59 CIN I 31 24 CIN II
9 21 27 64 32 24 CIN III
30 35 33 26 CIN II
36 23 34 NA CIN II
39 49 35 47 CIN III
37 24 CIN III
38 30 CIN III
40 32 CIN II
41 35 CIN III
Mean age 45.4 years Mean age 40.9 years Mean age 43.6 years Mean age 30.1 years Mean age 41.5 years
Details of the virgins (1–9) and patients (1–41) involved in the study, including their age at the time of sampling, and, for the patients, the grade of cervical neoplasia reported
following histological analysis of cervical tissue obtained at the same time. NA, not available.
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sis common in women with normal cytology (Bosch et al, 1995).
Therefore, virgins are the control group most likely to represent
HPV16 negativity, although it is not possible to establish whether
this is true in every case.
Preparation of CD4-enriched and -enriched T-cell
populations
Unfractionated mononuclear (UM) cells were separated from
40–60ml heparinised blood samples by isopycnic centrifuga-
tion on lymphocyte separation medium (Lymphoprep; Nycomed,
Oslo, Norway) and cryopreserved in liquid nitrogen. CD4þ and
CD8þ T-cell depletions were carried out on UM cells using
antibody-coated magnetic beads (Dynal, Oslo, Norway) accord-
ing to the method previously described (Steele et al, 2002).
Depleted populations were used directly as responder cells in
the ELISPOT assay. FACS analysis using dual-labelled anti-
human CD8:FITC/anti-CD4:RPE, or the isotype-matched negative
control IgG1:FITC/IgG1:RPE (Serotec, UK) was carried out
each time to verify the depletions, and in order to calculate
the number of T cells of the relevant phenotype being added to
each well.
Preparation of HPV16 VLPs for use in the ELISPOT assays
A recombinant baculovirus containing the HPV16 L1 and L2 genes
was kindly provided by Professor M Stanley (Department of
Pathology, University of Cambridge). HPV16 VLPs were produced
following the infection of SF9 insect cells, and were purified on
caesium chloride gradients according to published methods (Cubie
et al, 1998).
ELISPOT assay of IFN-c release
Overlapping synthetic peptides (30–35mers; Alta Bioscience,
Birmingham, UK) covering the entire primary sequences of the
HPV16 E6, E7 and E4 proteins (overlapping by 14–16 amino acids;
sequences shown in Table 2), and baculovirus-expressed HPV16
VLPs comprising both L1 and L2 were used to screen for CD4þ
and CD8þ T-cell responses using an ELISPOT assay of IFN-g
release (ELISPOT assay for human interferon-g; Mabtech,
Sweden). The ELISPOT assay procedure has been published
previously (Steele et al, 2002). Briefly, CD4- or CD8-enriched
responder cell populations were used at 4 10
5cells per well (in
duplicate) and peptides were added to a final concentration of
10mgml
 1. A negative control well with no peptide or VLP and a
positive control well containing cells and 0.2% PHA-P (Difco
Laboratories) instead of peptide were included for every sample.
The plates were counted using an automated system (AID,
Strasbourg, Germany) and background counts obtained in the
absence of peptide or VLP were subtracted. An ELISPOT response
among the patient group was only considered positive if the
number of spots obtained fell above a negative cutoff value. These
were calculated for every peptide and the VLP preparation, and
taken as 2 standard deviations (s.d.) above the mean of the counts
obtained using the negative control group comprising nine age-
matched female virgins.
Enzyme-linked immunosorbent assay (ELISA) to
determine HPV16 antibody levels
Purified baculovirus-expressed HPV16 VLPs (a kind gift from
Professor Martin Sapp, University of Mainz, Mainz, Germany)
were used in an ELISA to determine HPV16-specific antibody
levels in plasma samples obtained from each subject. This source
of VLPs was unsuitable for use in the ELISPOT assay due to
problems with toxicity. An ELISA method for detection of HPV1
VLP-specific antibodies has been published by us recently (Steele
et al, 2002). The procedure used here for HPV16 VLPs was the
same, except that a biotinylated second antibody and a peroxidase-
labelled StreptABComplex (Dako) were employed to increase the
sensitivity. Antibody levels were quantitated by relating the
absorbancies to that obtained from the positive control, an anti-
HPV16 L1 antibody, (Camvir 1, Abcam, UK) run under standard
conditions on every assay plate. The negative cutoff value was
taken as two standard deviations above the mean of the
absorbencies obtained using the virgin controls.
RESULTS
To define the frequency and spectrum of T-cell responses to
HPV16, we used five HPV16 proteins as targets; E6 and E7 are the
main transforming proteins and are expressed early in the
infection cycle, E4 is an abundant protein that is expressed at an
intermediate and late stage, and the capsid proteins L1 and L2
appear at later stages of the life cycle. Overlapping synthetic
peptides covering the entire primary sequence of E6, E7 and E4
(30–35mers; sequences are shown in Table 2) were used in an
ELISPOT assay of IFN-g release. It is important to note that
similar-length peptides have been used successfully in other
human immunological studies, including ELISPOT assays, to
detect HPV-specific T-cell responses (van der Burg et al, 2001; de
Jong et al, 2002, 2004; Welters et al, 2003). Human papillomavirus
16 VLPs were used as a source of L1 and L2 antigens in the
ELISPOT assay.
T-cell reactivity was detected in the majority of patients
To determine whether responding IFN-g-secreting T cells in the
ELISPOT were CD8þ or CD4þ, peripheral blood lymphocytes
were negatively depleted using magnetic beads. FACS analysis of
the CD4- or CD8-depleted T-cell populations revealed that in
nearly all cases there was a depletion of greater than 99% of the
appropriate T-cell subset (data not shown). The results of the
ELISPOT assays are shown in Figure 1 and the data are
summarised in Figure 2. We demonstrated either CD4þ or
Table 2 Sequences of the 30–35mer peptides (overlapping by 14–16
amino acids) covering HPV16 E6, E7 and E4 proteins used to screen for
CD4+ and CD8+ T-cell responses in ELISPOT assays of IFN-g release
aa
HPV16 E6 sequences
MHQKRTAMFQDPQERPRKLPQLCTELQTTIHDI 1–33
KLPQLCTELQTTIHDIILECVYCKQQLLRREV 18–49
ECVYCKQQLLRREVYDFAFRDLCIVYRDGNPYA 36–68
FRDLCIVYRDGNPYAVCDKCLKFYSKISEYRHY 54–86
KCLKFYSKISEYRHYCYSVYGTTLEQQYNKPLC 72–104
YGTTLEQQYNKPLCDLLIRCINCQKPLCPEEK 91–122
RCINCQKPLCPEEKQRHLDKKQRFHNIRGRWT 109–140
DKKQRFHNIRGRWTGRCMSCCRSSRTRRETQL 127–158
HPV16 E7 sequences
MHGDTPTLHEYMLDLQPETTDLYCYEQLNDSS 1–33
TDLYCYEQLNDSSEEEDEIDGPAGQAEPDRAHYNIV 20–55
AGQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDI 42–76
STLRLCVQSTHVDIRTLE DLLMGTLGIVCPICSQKP 63–98
HPV16 E4 sequences
MADPAAATKYPLLKLLGSTWPTTPPRPIPKPSP 1–33
WPTTPPRPIPKPSPWAPKKHRRLSSDQDQSQTPET 20–54
RLSSDQDQSQTPETPATPLSCCTETQWTVLQSSLHL 41–76
TETQWTVLQSSLHLTAHTKDGLTVIVTLHP 63–92
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Figure 1 CD4þ (on the left side of the figure) and CD8þ (on the right side of the figure) T-cell reactivities to HPV16 E6, E7, E4 peptides and HPV16
virus-like particles. CD4þ and CD8þ enriched responder cell populations from each patient were screened against 30–35mer peptides (overlapping by
14–16 amino acids) covering the entire primary sequences of the HPV16 E6, E7 and E4 proteins (sequences shown using an ELISPOT assay of interferon-g
release). The assay employed 4 10
5 responder cellswell
 1 (in duplicate), and both the peptides and the VLPs were used at a concentration of 10mgml
 1.
Responses obtained from the negative control group comprising nine age-matched female virgins were used to establish the negative cutoff values for each
peptide and the VLPs (meanþ2 s.d.). Positive responses are those which fall above the negative cutoff value (—), and the patient number is indicated.
Results are expressed as the number of spots obtained per 1 10
6T cells of the appropriate phenotype added to each well. These figures were calculated
following FACS analysis of depleted cell samples. Any background reactivity in the absence of peptide or VLPs has been subtracted.
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sCD8þ T-cell reactivity in 78% (32 out of 41) of the patient
samples tested, with 34% (14 out of 41) showing both CD4 and
CD8 responses (Figure 2A). Among the various disease grades,
the frequency of ELISPOT responders overall was: no CIN, 83%;
low-grade disease, 87.5%; high-grade disease, 69%; cervical cancer,
80% (Figure 2B).
The majority of the control samples showed little or no
T-cell reactivity, with the exception of numbers 5 and 9, both of
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Figure 1 (Continued)
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swhich demonstrated responses to a few peptides, particularly
those covering HPV16 E6 (Figure 1). Although this increased
the negative cutoff point quite considerably in some cases,
it would be incorrect to eliminate these samples from the
study.
CD8 responses were observed more often than CD4
responses
The results of the ELISPOT assays showed that CD8þ T-cell
reactivity occurred at almost twice the frequency of CD4þ
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sreactivity (Figure 2A). CD4 responses were detected in 39% (16 out
of 41) of patients, and CD8 responses in 73% (30 out of 41). A
similar percentage of women gave CD8þ T-cell responses in each
patient group: no CIN (75%; nine out of 12), low-grade disease
(75%; six out of eight), high-grade disease (69%; 11 out of 16) and
cervical cancer (80%; four out of five) (Figure 2C). In contrast,
CD4þ responses were more frequent among the women with no
CIN (50%; six out of 12) or with cervical cancer (60%; three out of
five), than among those with low-grade (37.5%; three out of eight)
and high-grade disease (25%; four out of 16) (Figure 2C). It is the
decreased number of responders in these last two groups,
particularly those with high-grade disease, which is responsible
for our finding that CD4þ T-cell reactivity was much less
common overall.
There was no significant difference in the magnitude of CD4 or
CD8 responses obtained among patient groups (Figure 1). The
greatest CD4þ T-cell response (746 spots per 1 10
6 CD4þ T
cells) was obtained from a woman with high-grade disease (patient
12), using an E6 peptide (RCINCQKPLCPEEKQRHLDKKQRFH
NIRGRWT; aa 109–140). In a CD8 response, the highest frequency
of spots (1538 spots per 1 10
6 CD8þ T cells) was obtained from
a patient with no CIN (patient 27), again in response to an E6
peptide (KLPQLCTELQTTIHDIILECVYCKQQLLRREV; aa 18–49).
CD8 T-cell responses to HPV16 E6 are dominant
Differences in the antigen specificities of the CD4 and CD8
responses were also observed in the ELISPOT assays, although this
was not related to disease grade (Figure 2D). A similar number of
responses to E6 (50%), E7 (56%) and E4 (56%) peptides was seen
among the CD4-positive samples, but only 25% responded to
VLPs. There was, however, a very dominant CD8þ T-cell response
to peptides covering E6, with 93% of the CD8-positive samples
showing reactivity to this protein. CD8 responses to the other
proteins were far less common (E7 33%; E4 10%; VLP 7%). For
both CD4þ and CD8þ T-cell reactivity, many of the patients
responded to more than one protein and saw more than one
peptide on each (Figure 1). This was particularly noticeable with
patients 6 and 13 (no CIN), 11 (low-grade disease) and 12 (high-
grade disease).
Seropositivity increases with disease severity and is related
to positive T-cell reactivity
The serological status of all subjects in the study was assessed in
order to obtain additional information about HPV16 immune
status. Antibodies to HPV16 VLPs were detected in 20 out of the 41
(48.7%) plasma samples overall (Figure 3). In women with no CIN
and low-grade disease, only 33 and 25% had positive serology,
respectively. In contrast, higher frequencies of seropositivity were
seen among the women with high-grade disease (69%) and cervical
cancer (60%). The analysis revealed an increase in the frequency of
antibody positivity (but not titre) with disease severity. The
median antibody levels obtained were 0.04 (range: 0.025–0.52) for
the women with no CIN, 0.03 (range: 0–0.145) for those with low-
grade disease, 0.0975 (range: 0–0.385) for those with high-grade
disease and 0.12 (range: 0.015–0.48) for the cervical cancer
patients. The differences in median values among the disease
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sgroups were not statistically significant (P-values all greater than
0.187; Mann–Whitney test). All of the patient groups had
significantly higher titres than those obtained from the negative
control group of female virgins (P-values all less than 0.017;
Mann–Whitney test), with the exception of those women with low-
grade disease (P¼0.091).
Out of the 20 seropositives obtained in this study, 18 (90%)
showed either CD4þ or CD8þ T-cell reactivity to HPV16
peptides in the ELISPOT assays. In all, 15 samples (71%) out of
the 21 with negative serology also gave a T-cell response. These
samples were from patients who fell predominantly into the no
CIN or low-grade disease groups. Interestingly, the patients who
demonstrated T-cell responses to multiple peptides and proteins
(patients 6, 11, 12 and 13) (Figure 1) were seronegative, whereas
the samples with the highest antibody titres (patients 5, 8, 18, 18
and 31) were either negative in the ELISPOT assay, or demon-
strated T-cell responses to only a narrow spectrum of peptides.
DISCUSSION
Using CD4- and CD8-enriched populations of responder cells
isolated from 41 women with varying degrees of cervical disease
(Table 1), we have investigated the frequency and spectrum of
HPV16-specific CD4þ and CD8þ T-cell responses, using ELI-
SPOT assays of IFN-g release, to HPV16 E4, E6, E7, L1 and L2.
Significantly, in this study, cells were used directly ex vivo in the
ELISPOT assay, without undergoing any kind of in vitro
restimulation. We demonstrated either CD4þ or CD8þ T-cell
reactivity in the majority of the patient samples tested (78%), with
34% showing both CD4 and CD8 responses. There was little
difference in the magnitude of the responses obtained between the
CD4- or CD8-enriched populations (Figure 1), and among the
various disease grades we found no significant difference in the
frequency of ELISPOT responders overall (Figure 2B). The high
detection rate of responses ex vivo was encouraging, considering
the numerous reports suggesting that HPV-specific T cells are rare
in peripheral blood. This is probably due to the high sensitivity of
the ELISPOT assay, and the fact that the study was not restricted to
selected peptides with specific HLA restrictions, that may lower the
rate of detection.
Human papillomavirus-specific CD4þ T cells may play a
critical role in disease clearance
An effective CTL response might be important for HPV clearance.
Human papillomavirus 16-specific CTLs are more frequent in
women with cleared infection than those with newly diagnosed
Human papillomavirus 16-positive CIN (Nakagawa et al, 1997).
However, both CD4 and CD8 effectors have been shown to be
involved (Nakagawa et al, 2002). Our observation that the
frequency of CD4 responders varies among the disease grades
suggests that the CD4þ T-cell response might be critically
involved in HPV clearance. The patients with low- and high-grade
disease showed CD4 reactivity less frequently. These women are
more likely to have progressive disease than those patients with no
CIN, and it is possible that their lack of CD4 T-cell reactivity is
contributing to progression. Notably, another study has used
similar protocols to examine T-helper responses to HPV16 E2, E6
and E7 peptides in healthy individuals and in women with cervical
carcinoma (Welters et al, 2003). CD4 reactivity was found to be far
more common among the group of normal donors than the cancer
patients, again suggesting that HPV16-specific CD4þ T-cell
immunity is important for disease protection. Evidence from
allograft recipients and HIV-infected individuals (Palefsky et al,
1999) also indicates that it is the absolute deficit in CD4þ T cells
which is the important risk factor for HPV-induced disease and
associated neoplastic progression in the immunocompromised
individual, and CD4þ T cells have been shown to be prominent in
resolving cutaneous (Iwatsuki et al, 1986) and genital warts
(Coleman et al, 1994). Other recent studies looking for HPV-
specific T cells in peripheral blood also suggest that helper T cells
play a central role in the control of HPV infection, disease
regression and clearance (Kadish et al, 2002; de Jong et al, 2004).
Human papillomavirus-specific immunity is different in
cancer
We found the highest number of CD4 responders in the small
group of patients with cancer. This is in agreement with some
reports (de Gruijl et al, 1996a,b, 1998; de Jong et al, 2004), but not
others, where CD4 responses have been found to be decreased in
cancer (Luxton et al, 1996, 1997; Nakagawa et al, 1996; Hopfl et al,
2000; van der Burg et al, 2001; Welters et al, 2003). However, all of
these studies use different methodologies and the majority used in
vitro restimulation protocols. There seems to be little doubt that T-
cell responses in patients clearing cervical HPV infection are
different from those progressing to cervical cancer. It is
conceivable that an ineffective HPV-specific CD4þ T-cell
response early during infection will allow HPV to persist and the
establishment of high-grade disease. However, it seems that the
presence of a tumour will eventually induce CD4þ T-cell
immunity. This could be because the tumour will eventually
breach the basement membrane of the epithelium and viral
antigens will become exposed to the immune system. In invasive
carcinoma, there will also be an increase in the amount of infected
tissue and subsequently viral load. Indeed, HPV16 responses have
been shown to be dependent on antigen dose in experiments using
a murine model in which viral antigen is expressed in
keratinocytes and mimics the natural route of infection (Chambers
et al, 1994). A surprisingly high frequency of HPV-specific CD4þ
T-cell responses in women with cervical carcinoma compared to
those with high-grade CIN has also been observed in a similar
study published recently by de Jong et al (2004). They also looked
at cytokine production and their results suggested that cervical
cancers do not provide the appropriate proinflammatory environ-
ment for the induction of a potent and well-polarised T-cell
response, and that if CD4þ T-cell priming occurs at this stage of
disease it will most likely result in an ineffective antitumour
response.
CD8þ T-cell responses to HPV16 E6 are dominant
Differences in the antigen specificities of the CD4 and CD8
responses were also observed in this study. There was a very
dominant CD8þ T-cell response to peptides covering HPV16 E6
(Figure 1A), a protein known to be critical for malignant
transformation and maintenance of the transformed phenotype.
It could be concluded from our results that E6-specific CD8þ T
cells do not play a major role in HPV clearance because they were
so predominant across all disease grades (Figure 2C). This is
supported by other studies where HPV16 E6-specific CTLs have
been shown to be associated with disease and viral persistence
(Bontkes et al, 2000; Nakagawa et al, 2000).
Antigen specificity and disease severity are unrelated
There was no obvious relationship between antigen specificity and
disease severity for either CD4þ or CD8þ T-cell reactivities. This
may be explained by the fact that the immune system is probably
primed early on during productive infection when all of the HPV16
proteins are being expressed. Human papillomavirus 16 infection
of the cervix is believed to become less productive as the disease
progresses, and, following malignant transformation when HPV
DNA becomes integrated in the host genome (Cullen et al, 1991),
the expression of all viral proteins, other than E6 and E7, ceases.
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lesions (Doorbar et al, 1997) and it is likely that HPV-specific
memory T cells are already present.
Cross-reacting T-cell responses
Given the degree of sequence homology between related HPV
types, it is possible that we may have detected crossreactive
responses to other genital HPVs. T-cell crossreactivity usually
requires conserved blocks of sequence identity and this would be
expected to restrict the number of epitopes which would be shared
between virus types. Crossreaction is most likely to be a problem
with L1, which is the most highly conserved of the HPV proteins
tested. However, we have employed VLPs that contain type-
specific epitopes to screen for L1 and L2 responses. E6 and E7
proteins only exhibit approximately 40% sequence homology
between related virus types, and E4 sequences are highly type-
specific. The problem of crossreaction has been thoroughly
investigated in our recent study using HPV1 (Steele et al, 2002),
and we believe that the responses obtained here are HPV16-
specific. If the problem of crossreaction with the common
cutaneous virus types existed, this would have been observed
among the negative control group.
Seropositivity is related to positive T-cell reactivity
In this study, antibody status did seem to be a good predictor of T-
cell reactivity, since 18 out of the 20 samples with positive serology
gave a T-cell response, and only three out of nine patients who
demonstrated no T-cell reactivity had antibodies. The converse,
however, was not true since out of the 32 patients who responded
in the ELISPOT, only 18 were seropositive. It is difficult to draw
conclusions about those patients who were seronegative due to the
lag phase of several months between infection with the virus and
the appearance of antibodies in the blood (Carter et al 2000), and
the fact that antibody levels eventually diminish. Thus, negative
serology does not mean that the individual has never been infected
or is unlikely to possess HPV16-specific memory T cells.
We found that the patients who demonstrated T-cell responses
of multiple specificities (patients 6, 11, 12, and 13) were
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Figure 3 Relative HPV16-specific antibody levels obtained using an
ELISA that employed HPV16 L1-VLPs. Antibody levels were quantitated by
relating the absorbencies obtained for each sample to that obtained from
the positive control (Camvir 1) run under standard conditions on every
assay plate. The negative control providing the negative cutoff value (—)
was taken as 2 s.d. above the mean of the absorbencies obtained using the
virgin controls. Background readings, where no antigen had been bound to
the plate, were subtracted from experimental readings in every case.
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had the highest antibody titres (patients 5, 8, 18, 18 and 31). One
explanation for these results is that the antibody response is slower
than the T-cell response. Perhaps, the women showing multiple T-
cell reactivities have only recently encountered the virus, and have
large numbers of effector T cells, but the antibody response is not
yet established. Conversely, in the other group of women with low
T-cell reactivity and high antibody titres, the primary effector T-
cell response may have subsided, but the serological response is
still present and helping to prevent re-infection. It is difficult to
define precisely the relationship between T-cell reactivity and
antibody status; more knowledge is required about the relative
timescales and roles of the T- and B-cell responses to HPV during
natural infection.
In summary, we have shown that ELISPOT assays of IFN-g
release are capable of revealing T-cell reactivities to HPV16
antigens in women with cervical dysplasia and can be used to
establish the spectrum of T-cell responses induced during natural
infection. The ELISPOT assay is becoming established as a good
method for charting HPV-specific immunity, both during natural
infection and following vaccination (van der Burg et al, 2001; de
Jong et al, 2002, 2004; Steele et al, 2002; Baldwin et al, 2003;
Welters et al, 2003; Smith et al, 2004; Smyth et al, 2004). Setting the
vaccination studies aside, there are differences between the
conclusions drawn from the studies looking at natural immunity
and those obtained in this study. There are several possible
explanations for this. Firstly, we have examined responses directly
ex vivo, which is more likely to be representative of the in vivo
situation. The majority of the other studies employed an in vitro
stimulation step prior to ELISPOT analysis. Secondly, we
established negative cutoff values using a valid negative control
group that obviously minimises the problems associated with
nonspecificity. Thirdly, many of the published studies have
concentrated on HPV-specific responses in normal individuals.
By looking at the healthy population, these studies are likely to be
detecting predominantly memory T-cell reactivity, whereas we
were studying women with recent or current disease, and are
therefore likely to be detecting effector populations as well as
memory.
The results from the current study suggest that there are
differences in how viral antigens are handled by the immune
system during progressive disease of the cervix. In order to define
this more precisely, more noninterventional prospective studies
will be required, although there are obvious ethical problems
associated with this. The vast majority of women in this cohort
underwent surgical excision that is likely to have an effect on
HPV16 immunity, and so a prospective study would not be
possible. Defining the role played by HPV16-specific T cells in the
natural history of cervical disease will aid the development of
immunological assays to determine the risk of CIN progression,
and therefore the management of premalignant and malignant
HPV-associated neoplasia.
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